[Skip to Navigation]
Views 2,051
Citations 0
Editorial
April 6, 2021

Celecoxib for Stage III Colon Cancer

Author Affiliations
  • 1Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
  • 2Oxford University Hospitals Trust, Oxford, United Kingdom
  • 3Department of Oncology, University of Oxford, Oxford, United Kingdom
JAMA. 2021;325(13):1257-1258. doi:10.1001/jama.2021.2651

Observational studies have linked aspirin and selective cyclooxygenase-2 (COX-2) inhibitors to prevention of colorectal adenomas and colorectal cancer, and reduction in recurrence following resection or improved survival for patients with advanced or metastatic disease.1-3 There are plausible mechanistic hypotheses linking inhibition of prostaglandin synthesis, nuclear factor κB activation,4 and the transcription factor RUNX15 to the anticancer effects of aspirin and celecoxib. In addition, there is evidence from a meta-analysis across multiple studies of the potential effects in terms of enhanced response rates when COX-2 inhibition was added to standard chemotherapy in advanced colorectal cancer and other solid cancers. However, this improvement did not translate to an improvement in 1-year survival.6

×